Management of monogenic diabetes in pregnancy:A narrative review  

作　　者：Mohammad Sadiq Jeeyavudeen Sarah R Murray Mark W J Strachan 

机构地区：[1]Metabolic Unit,Western General Hospital,Edinburgh EH42XU,United Kingdom [2]MRC Centre for Reproductive Health,University of Edinburgh Queen’s Medical Research Institute,Edinburgh EH164TJ,United Kingdom

出　　处：《World Journal of Diabetes》2024年第1期15-23,共9页世界糖尿病杂志（英文版）（电子版）

摘　　要：Pregnancy in women with monogenic diabetes is potentially complex,with significant implications for both maternal and fetal health.Among these,maturity-onset diabetes of the young(MODY)stands out as a prevalent monogenic diabetes subtype frequently encountered in clinical practice.Each subtype of MODY requires a distinct approach tailored to the pregnancy,diverging from management strategies in non-pregnant individuals.Glucokinase MODY(GCK-MODY)typically does not require treatment outside of pregnancy,but special considerations arise when a woman with GCK-MODY becomes pregnant.The glycemic targets in GCK-MODY pregnancies are not exclusively dictated by the maternal/paternal MODY genotype but are also influenced by the genotype of the developing fetus.During pregnancy,the choice between sulfonylurea or insulin for treating hepatocyte nuclear factor 1-alpha(HNF1A)-MODY and HNF4A-MODY depends on the mother’s specific circumstances and the available expertise.Management of other rarer MODY subtypes is individu-alized,with decisions made on a case-by-case basis.Therefore,a collaborative approach involving expert diabetes and obstetric teams is crucial for the compre-hensive management of MODY pregnancies.

关 键 词：Diabetes Pregnancy Maturity-onset diabetes of the young INSULIN SULPHONYLUREA GLUCOKINASE Hepatocyte nuclear factor 1-alpha hepatocyte nuclear factor 1-beta and hepatocyte nuclear factor 4-alpha 

分 类 号：R587.2[医药卫生—内分泌]